Cochlear (ASX:COH) first half-results missing estimates is "disappointing" due to upgrades to its Nuclear 8 sound processor, which caused a decline in services revenue, according to Feb. 14 noted by Jarden Research.
The company reported Friday that its six-month earnings per diluted share rose to AU$3.125 from AU$2.913 per diluted share a year earlier. Total revenue for the half year ended Dec. 31, 2024, was AU$1.17 billion.
Jarden believes that COH's plan to launch its next-generation implant and the introduction of its Kanso 3 sound processor by mid-2025 should strengthen its outlook for 2026.
The investment firm reaffirmed a neutral rating and a price target of AU$263.75 on COH.
Shares of COH rose 4% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.